Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Clinical trial NCT06569147 · RECRUITING
Trial details
- NCT number
- NCT06569147
- Sponsor
- Dana-Farber Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-01
- Primary completion
- 2029-01-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.